NEW YORK (GenomeWeb) – Australian molecular diagnostics company SpeeDx is picking up the pace on its path to the clinic, the firm reports.
Founded on proprietary nucleic acid enzymes called MNAzymes and unique primer and isothermal signaling technologies, the company has pursued parallel paths — co-developing diagnostics with licensees and nurturing its own IVD pipeline.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
